This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Today's Health Winners and Losers

Shares of Beckman Coulter (BEC) were among the health-related losers Friday, falling 5% after the maker of biomedical testing instruments posted mixed fourth-quarter results and issued lower-than-expected first-quarter guidance.

In the fourth quarter, the company earned $17.8 million, or 28 cents a share, on sales of $655.5 million. Excluding items, the company earned $46.9 million, or 73 cents a share. Analysts polled by Thomson First Call expected a lower profit of 72 cents a share, but higher sales of $668.6 million. During the year-earlier period, the company earned $59.8 million, or 91 cents a share, on sales of $693 million.

Looking ahead, Beckman Coulter sees first-quarter earnings of 30 cents to 40 cents a share, including stock-based compensation costs of 5 cents a share. Analysts project earnings, excluding stock-based compensation costs, of 64 cents a share. The company predicts sales of $555 million to $575 million, below analysts' target of $582.1 million. For 2006, Beckman Coulter continues to see earnings of $2.70 to $2.90 a share, including stock-based compensation costs of about 20 cents a share, on sales of $2.53 billion to $2.6 billion. Analysts project earnings, excluding stock-based compensation costs, of $3.02 a share on sales of $2.56 billion. Shares were trading down $3.25 to $56.91.

American Pharmaceutical Partners (APPX) rose 3% after the drugmaker posted fourth-quarter earnings that topped forecasts. The company earned $23.4 million, or 32 cents a share, on sales of $144.8 million. Excluding items, the company earned $28.2 million, or 38 cents a share. Analysts expected earnings of 35 cents a share, before items. A year earlier, the company earned $21.9 million, or 30 cents a share, on sales of $122.6 million. Shares were trading up $1.02 to $32.63.

Shares of NuVasive (NUVA) fell 2.5% after a lower-than-expected sales guidance overshadowed fourth-quarter results that topped expectations. The medical device company posted a fourth-quarter loss of $4.2 million, or 17 cents a share, on sales of $18.6 million. Excluding items, the company reported a loss of $3.4 million, or 14 cents a share. Analysts expected a loss of 15 cents a share, before items, on sales of $18.3 million. During the year-earlier quarter, the company recorded an adjusted loss of $1.9 million, or 8 cents a share, on sales of $11.8 million.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,902.29 -12.78 -0.08%
S&P 500 1,962.05 -2.63 -0.13%
NASDAQ 4,399.5090 +3.3050 0.08%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs